ARCHIVES

Genentech Reps Not Welcome: Hospitals Urge Drug Maker to Reverse Policy On Supplying Avastin, Rituxan, & Herceptin

This article is from The Cancer Letter archive.

Vol. 40 No. 39 | October 17, 2014

Download PDF Visit The Full Archive

Related Articles

ODAC Recommends TICE BCG Approval For Recurrent Bladder Cancer Prevention

January 10, 1997

UCSF Gets $20 Million For Stem Cell Research Building

February 4, 2011

Three Geneticists Of “Knockout” Mice Fame Win Lasker Award For Basic Research.

September 28, 2001

HAI Delivery Extends Survival In Patients With Liver Metastasis

March 31, 2006

CPRU Program Gets Basic Concept Approval

October 2, 1987

16 Institutions Win NCI Awards for Phase I Trials

May 2, 2003